Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neptunus Bioengineering Holdings To Transfer Beidouxing Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Neptunus Bioengineering Holdings plans to transfer its 100 percent stake in Changchun Beidouxing Pharmaceutical for RMB 40 million to Texas Petroleum. In addition, the company and its subsidiary Neptunus Interlong Bio-technique will sign a letter of intent on equity transfer and assets acquisition. To beef up Interlong's profit-making capability, Neptunus Bioengineering and its holding subsidiary Neptunus Medicine intend to sell their respective 75 percent and 5 percent stakes in Fuzhou Neptunus Futao Pharmaceuticals to Interlong. Interlong will on its part transfer its interferon and interleukin business to Neptunus Medicine. (Click here for more - Chinese Language)

You may also be interested in...

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Alvogen Aims To Be First On EU Pazopanib

Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts